NPHC's burn rate is due to mostly R&D and with that they had to hire an additional 10 people, along with investor conferences, etc.
My point is that J&J probably does own their shelf space, but there is no way XCHO could afford that and this why we saw Cobroxin placed where it was on the shelves.